Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial.
de Vlam K, Maksymowych WP, Gallo G, Rahman P, Mease P, Krishnan V, McVeigh CJ, Lisse J, Zhu D, Bolce RJ, Conaghan PG. de Vlam K, et al. Among authors: bolce rj. Rheumatol Ther. 2024 Jun;11(3):691-707. doi: 10.1007/s40744-024-00660-7. Epub 2024 Apr 18. Rheumatol Ther. 2024. PMID: 38637464 Free PMC article.
Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry.
Gavigan K, Nowell WB, Hunter T, Curtis JR, Malatestinic WN, Bolce RJ, Lisse JR, Walsh J. Gavigan K, et al. Among authors: bolce rj. Rheumatol Ther. 2022 Apr;9(2):663-677. doi: 10.1007/s40744-022-00428-x. Epub 2022 Feb 21. Rheumatol Ther. 2022. PMID: 35191010 Free PMC article.
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M. van der Horst-Bruinsma IE, et al. Adv Ther. 2022 Jun;39(6):2806-2819. doi: 10.1007/s12325-022-02132-2. Epub 2022 Apr 16. Adv Ther. 2022. PMID: 35429281 Free PMC article. Clinical Trial.
Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication.
Nowell WB, Gavigan K, Hunter T, Bolce RJ, Lisse JR, Himelein C, Dubey S, Curtis JR, Walsh JA. Nowell WB, et al. Among authors: bolce rj. Rheumatol Ther. 2022 Apr;9(2):509-520. doi: 10.1007/s40744-021-00417-6. Epub 2021 Dec 27. Rheumatol Ther. 2022. PMID: 34958453 Free PMC article.
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.
Landewé RBM, Poddubnyy D, Rahman P, Van den Bosch FE, Bolce R, Liu Leage S, Lisse JR, Park SY, Gensler L. Landewé RBM, et al. Ann Rheum Dis. 2023 Feb;82(2):212-216. doi: 10.1136/ard-2022-222731. Epub 2022 Sep 13. Ann Rheum Dis. 2023. PMID: 36100350 Free PMC article. Clinical Trial.
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
McGonagle D, Kavanaugh A, McInnes IB, Kristensen LE, Merola JF, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. McGonagle D, et al. Rheumatology (Oxford). 2024 Feb 10:keae060. doi: 10.1093/rheumatology/keae060. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38341669
25 results